Opzelura Explained: How This JAK Inhibitor Cream Treats Eczema

Opzelura (ruxolitinib) cream is a prescription JAK inhibitor cream approved by the US Food and Drug Administration (FDA) to treat mild, moderate, or severe atopic dermatitis (eczema) in adults and children aged 12 years and older who are not adequately controlled with topical corticosteroids or who are intolerant of them.

How Opzelura Cream Works:

Opzelura cream belongs to a class of drugs known as Janus Kinase (JAK) inhibitors. JAK enzymes play a crucial role in the inflammatory response that leads to eczema. Opzelura works by blocking the activity of specific JAK enzymes, particularly JAK1 and JAK2, thereby reducing inflammation and alleviating eczema symptoms.

Application:

Opzelura cream is typically applied to the affected skin twice daily, once in the morning and once in the evening. The cream should be rubbed in gently until it is absorbed. It is important to avoid applying Opzelura cream to areas of the skin that have open wounds or infections.

Benefits:

Opzelura cream has demonstrated efficacy and safety in clinical trials for the treatment of eczema. It has been shown to effectively reduce the signs and symptoms of eczema, including itching, redness, and skin lesions. Additionally, Opzelura cream is well-tolerated with a low risk of side effects, making it a suitable treatment option for many individuals with eczema.

Side Effects:

The most common side effects associated with Opzelura cream include:

- Application site reactions, such as redness, burning, or itching.

- Respiratory infections, such as the common cold.

- Acne.

- Folliculitis (inflammation of hair follicles).

- Herpes simplex virus infections (e.g., cold sores).

Dosage:

The recommended dosage of Opzelura cream is one application twice daily to the affected skin. The maximum recommended daily dose is 15 grams.

Special Considerations:

It is important to note that Opzelura cream should not be used by individuals with certain medical conditions, such as severe liver or kidney disease, active tuberculosis, or a weakened immune system. Additionally, Opzelura cream should not be used during pregnancy or breastfeeding.

Before using Opzelura cream, it is essential to consult a healthcare professional to determine if it is the right treatment option and to discuss any潜在风险或注意事项.